Johnson & Johnson (JNJ) Stock Price, News & Analysis

Johnson & Johnson logo
$228.37 -0.02 (-0.01%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$228.54 +0.17 (+0.08%)
As of 06/18/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Johnson & Johnson Stock (NYSE:JNJ)

Advanced

Key Stats

Today's Range
$227.60
$232.75
50-Day Range
$221.17
$241.13
52-Week Range
$149.04
$251.71
Volume
18.99 million shs
Average Volume
7.78 million shs
Market Capitalization
$549.73 billion
P/E Ratio
26.40
Dividend Yield
2.35%
Price Target
$253.04
Consensus Rating
Moderate Buy

Company Overview

Johnson & Johnson Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
92nd Percentile Overall Score

JNJ MarketRank™: 

Johnson & Johnson scored higher than 92% of companies evaluated by MarketBeat, and ranked 39th out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Johnson & Johnson has received a consensus rating of Moderate Buy. The company's average rating score is 2.74, and is based on no strong buy ratings, 20 buy ratings, 7 hold ratings, and no sell ratings.

  • Upside Potential

    Johnson & Johnson has a consensus price target of $253.04, representing about 10.8% upside from its current price of $228.37.

  • Amount of Analyst Coverage

    Johnson & Johnson has been the subject of 18 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Johnson & Johnson's stock forecast and price target.
  • Earnings Growth

    Earnings for Johnson & Johnson are expected to grow by 8.90% in the coming year, from $11.57 to $12.60 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Johnson & Johnson is 26.40, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.66.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Johnson & Johnson is 26.40, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 24.73.

  • Price to Earnings Growth Ratio

    Johnson & Johnson has a PEG Ratio of 2.24. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Johnson & Johnson has a P/B Ratio of 6.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Johnson & Johnson's valuation and earnings.
  • Percentage of Shares Shorted

    0.97% of the float of Johnson & Johnson has been sold short.
  • Short Interest Ratio / Days to Cover

    Johnson & Johnson has a short interest ratio ("days to cover") of 2.95, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Johnson & Johnson has recently increased by 1.60%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Johnson & Johnson pays a meaningful dividend of 2.35%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Johnson & Johnson has been increasing its dividend for 64 years.

  • Dividend Coverage

    The dividend payout ratio of Johnson & Johnson is 61.97%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Johnson & Johnson will have a dividend payout ratio of 42.54% next year. This indicates that Johnson & Johnson will be able to sustain or increase its dividend.

  • Read more about Johnson & Johnson's dividend.
  • News Sentiment

    Johnson & Johnson has a news sentiment score of 1.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 115 news articles for Johnson & Johnson this week, compared to 13 articles on an average week.
  • Search Interest

    Only 146 people have searched for JNJ on MarketBeat in the last 30 days. This is a decrease of -5% compared to the previous 30 days.
  • MarketBeat Follows

    103 people have added Johnson & Johnson to their MarketBeat watchlist in the last 30 days. This is an increase of 194% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Johnson & Johnson insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,411,500.00 in company stock.

  • Percentage Held by Insiders

    0.16% of the stock of Johnson & Johnson is held by insiders.

  • Percentage Held by Institutions

    69.55% of the stock of Johnson & Johnson is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Johnson & Johnson's insider trading history.
Receive JNJ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Johnson & Johnson and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

JNJ Stock News Headlines

Johnson & Johnson (JNJ) Could Be a Great Choice
Goldman Sachs just told you what to buy (most people missed it)
Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - not chips, not funding, but power. Demand is growing 15% per year and the grid can't keep up. One small company makes the exact equipment these data centers need. They're sitting on $1.5 billion in orders, their hardware is already inside Musk's Colossus, and the stock still trades like a name nobody's heard of. Analyst Dylan Jovine is releasing the ticker for free.tc pixel
A green upward arrow, prescription drug packaging labeled Eli Lilly, and a stock market chart on a monitor.
3 Stocks Doing the Heavy Lifting in Healthcare’s Rebound (JNJ)
Led by Eli Lilly’s GLP-1 success, Humana’s expanding margins, and DexCom’s medtech growth, the healthcare sector is staging a major market rebound.
Illustrated graphic with a gold crown and the text "Dividend Kings" set against a classic library background.
3 Dividend Kings That Earn Their Crown Every Quarter
These 3 Dividend Kings combine decades of dividend growth with strong fundamentals, recession resistance, and long-term income potential...
See More Headlines

JNJ Stock Analysis - Frequently Asked Questions

Johnson & Johnson's stock was trading at $207.07 at the beginning of 2026. Since then, JNJ stock has increased by 10.3% and is now trading at $228.3670.

Johnson & Johnson (NYSE:JNJ) announced its quarterly earnings results on Tuesday, April, 14th. The company reported $2.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.68 by $0.02. The company's quarterly revenue was up 9.9% on a year-over-year basis.
Read the conference call transcript
.

The following companies are subsidiaries of Johnson & Johnson: Momenta Pharmaceuticals, TARIS Biomedical, Verb Surgical, Auris Health, Ci:z Holdings, Zarbee's Naturals, Orthotaxy, and more.

Johnson & Johnson's top institutional shareholders include Bank of America Corp DE (1.06%), Bank of New York Mellon Corp (0.91%), Dimensional Fund Advisors LP (0.66%) and Amundi (0.56%). Insiders that own company stock include & Johnson Johnson, Jennifer L Taubert, Kathryn E Wengel, Peter Fasolo, William Hait, Timothy Schmid, Vanessa Broadhurst, Robert J Decker and Mark A Weinberger.
View institutional ownership trends
.

Shares of JNJ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Johnson & Johnson investors own include Cuisine Solutions (CUSI), InnerScope Hearing Technologies (INND), UnitedHealth Group (UNH), Gilead Sciences (GILD), Corning (GLW), NextEra Energy (NEE) and Devon Energy (DVN).

Company Calendar

Last Earnings
4/14/2026
Record date for 6/9 Dividend
5/26/2026
Ex-Dividend for 6/9 Dividend
5/26/2026
Dividend Payable
6/09/2026
Today
6/19/2026
Next Earnings (Estimated)
7/15/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Large Cap Pharma
Sub-Industry
Pharmaceuticals
Current Symbol
NYSE:JNJ
CIK
200406
Employees
138,200
Year Founded
1886

Price Target and Rating

High Price Target
$285.00
Low Price Target
$190.00
Potential Upside/Downside
+10.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.74
Research Coverage
27 Analysts

Profitability

EPS (Trailing Twelve Months)
$8.65
Trailing P/E Ratio
26.40
Forward P/E Ratio
19.74
P/E Growth
2.24
Net Income
$26.80 billion
Net Margins
21.83%
Pretax Margin
25.88%
Return on Equity
32.60%
Return on Assets
13.29%

Debt

Debt-to-Equity Ratio
0.46
Current Ratio
1.03
Quick Ratio
0.77

Sales & Book Value

Annual Sales
$94.19 billion
Price / Sales
5.84
Cash Flow
$14.11 per share
Price / Cash Flow
16.18
Book Value
$33.85 per share
Price / Book
6.75

Miscellaneous

Outstanding Shares
2,407,220,000
Free Float
2,403,365,000
Market Cap
$549.73 billion
Optionable
Optionable
Beta
0.26

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NYSE:JNJ) was last updated on 6/19/2026 by MarketBeat.com Staff.
From Our Partners